Accession Number: | 0001209191-20-037226 |
Date: | 2020-06-15 |
Issuer: | KARYOPHARM THERAPEUTICS INC. (KPTI) |
Original Submission Date: |
SHACHAM SHARON
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON, MA 02459
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-06-15 | M | 7,143 | a | $0.03 | 763,632 | direct | ||
COMMON STOCK | 2020-06-15 | S | 7,143 | d | $16.38 | 756,489 | direct | ||
COMMON STOCK | 2020-06-15 | M | 357 | a | $0.03 | 756,846 | direct | ||
COMMON STOCK | 2020-06-15 | S | 357 | d | $16.20 | 756,489 | direct | ||
COMMON STOCK | 2020-06-15 | 0 | $0.00 | 555,122 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 0.033 | 2020-06-15 | deemed execution date | M | 7,143 (d) | 2020-10-31 | common stock 7,143 | $0.03 | 16,424 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 0.033 | 2020-06-15 | deemed execution date | M | 357 (d) | 2020-10-21 | common stock 357 | $0.03 | 0 | direct |
ID | footnote |
---|---|
f1 | these transactions were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. |
f2 | represents the weighted average sale price. these shares were sold in multiple transactions at prices ranging from $16.12 to $16.58, inclusive. the reporting person undertakes to provide upon request by the u.s. securities and exchange commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
f3 | this option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on november 1, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. |
f4 | this option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on october 22, 2011, and the remaining 75% vested in 36 equal monthly installments thereafter. |